Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teppei Yamaguchi

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Cancer Medicine|November 10, 2023
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620LTakehiro Uemura, Hirotsugu Kenmotsu, Daisuke Hazama, et al.
Japanese Journal of Clinical Oncology|January 25, 2024
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING studyHisao Imai, Takashi Kijima, Koichi Azuma, et al.
Plos Biology|September 26, 2015
HDAC1/2-Dependent P0 Expression Maintains Paranodal and Nodal Integrity Independently of Myelin Stability through Interactions with NeurofascinsValérie Brügger, Stefanie Engler, Jorge A Pereira, et al.
Lung Cancer (Amsterdam, Netherlands)|May 25, 2025
Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT studyAsuka Okada, Yoshihiko Sakata, Yuko Oya, et al.
Clinical Lung Cancer|June 29, 2025
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)Yoshihiko Sakata, Go Saito, Shinya Sakata, et al.
Lung Cancer (Amsterdam, Netherlands)|December 14, 2024
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort studyJun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, et al.
Lung Cancer (Amsterdam, Netherlands)|September 23, 2024
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trialRyota Shibaki, Daichi Fujimoto, Eisaku Miyauchi, et al.
Clinical Lung Cancer|January 3, 2026
Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424LShunichi Kataoka, Takehito Shukuya, Hiroshi Ohtsu, et al.
Lung Cancer (Amsterdam, Netherlands)|July 23, 2024
Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND)Daichi Fujimoto, Hidetoshi Hayashi, Kenta Murotani, et al.
Oncoimmunology|July 2, 2024
Candidate tumor-specific CD8<sup>+</sup> T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysisYusuke Sugita, Daisuke Muraoka, Ayako Demachi-Okamura, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Cancer Medicine|November 10, 2023
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620LTakehiro Uemura, Hirotsugu Kenmotsu, Daisuke Hazama, et al.
Japanese Journal of Clinical Oncology|January 25, 2024
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING studyHisao Imai, Takashi Kijima, Koichi Azuma, et al.
Plos Biology|September 26, 2015
HDAC1/2-Dependent P0 Expression Maintains Paranodal and Nodal Integrity Independently of Myelin Stability through Interactions with NeurofascinsValérie Brügger, Stefanie Engler, Jorge A Pereira, et al.
Lung Cancer (Amsterdam, Netherlands)|May 25, 2025
Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT studyAsuka Okada, Yoshihiko Sakata, Yuko Oya, et al.
Clinical Lung Cancer|June 29, 2025
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)Yoshihiko Sakata, Go Saito, Shinya Sakata, et al.
Lung Cancer (Amsterdam, Netherlands)|December 14, 2024
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort studyJun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, et al.
Lung Cancer (Amsterdam, Netherlands)|September 23, 2024
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trialRyota Shibaki, Daichi Fujimoto, Eisaku Miyauchi, et al.
Clinical Lung Cancer|January 3, 2026
Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424LShunichi Kataoka, Takehito Shukuya, Hiroshi Ohtsu, et al.
Lung Cancer (Amsterdam, Netherlands)|July 23, 2024
Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND)Daichi Fujimoto, Hidetoshi Hayashi, Kenta Murotani, et al.
Oncoimmunology|July 2, 2024
Candidate tumor-specific CD8<sup>+</sup> T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysisYusuke Sugita, Daisuke Muraoka, Ayako Demachi-Okamura, et al.
Pageof 6